Melatonin, the Tiny Pill That Might Ease Our Chronic Pain

Introduction: a sleep hormone that intrigues pain researchers

A discovery born from a synthesis of 23 clinical trials

A new synthesis led by the University of Sydney is a reminder that we never fully know a drug, even one we consider mundane. Melatonin, the supplement millions of people swallow every night to sleep better, might also relieve chronic musculoskeletal pain, according to a study published on June 30, 2026 in the scientific journal PAIN. The researchers, led by PhD candidate Kangchao Wu of the Musculoskeletal Research Hub at the Charles Perkins Centre, combed through 23 randomized clinical trials conducted in countries as varied as the United States, Russia, Brazil, Egypt and China.

In total, data from 2,028 adults were analyzed, a cohort large enough to lend weight to the conclusions, even though the authors themselves urge caution. Participants suffered from a range of conditions: chronic low back pain, osteoarthritis, fibromyalgia, or were recovering from procedures such as joint replacements and spinal surgeries.

An effect comparable to that of standard painkillers

What stands out in this research is the size of the measured effect. On average, melatonin reduced pain by roughly nine points on a 0-to-100 scale, and the trials judged most methodologically rigorous showed reductions closer to ten points. That magnitude, according to the researchers, is comparable to what is achieved with widely used medications such as opioids, nonsteroidal anti-inflammatory drugs and acetaminophen.

With musculoskeletal pain affecting up to 47% of the global population, according to estimates cited by the research team, a low-cost and widely accessible option could be a game changer for millions of people seeking alternatives to conventional pharmaceutical treatments, which are often accompanied by heavier side effects.

Understanding the link between sleep and chronic pain

A bidirectional relationship documented for a long time

Chronic pain and sleep disorders feed off each other in a loop well documented in the scientific literature: pain prevents good sleep, and lack of sleep in turn heightens sensitivity to pain, a phenomenon researchers call hyperalgesia. It is precisely this double action that makes melatonin interesting in the eyes of the study's authors.

According to Kangchao Wu, quoted in the university's press release, "for many patients, pain doesn't exist in isolation, and it's closely tied to poor sleep." He adds that melatonin "seems to target both at once, which makes it particularly useful for people managing chronic pain."

A measurable improvement in sleep quality

Beyond its effect on pain itself, the synthesis also found an improvement in sleep quality among participants who took melatonin, reinforcing the hypothesis of a dual-action mechanism. This observation is not trivial in a context where chronic sleep disorders remain largely undertreated across several Western health systems.

Still, the dose-response relationship remains unclear: the researchers did not identify a clear link between the administered dose and the extent of relief, which means an "optimal" universal dose cannot yet be recommended based on current data.

Variable doses depending on the condition treated

Between 3 and 10 milligrams for chronic pain

The protocols studied across the 23 trials used varied doses depending on the condition treated and the clinical context. For chronic musculoskeletal pain, doses generally ranged from 3 to 10 milligrams, with 3 mg per day being the most frequently used dose in the protocols studied. For postoperative pain, doses varied between 1 and 10 mg, with a range of 5 to 6 mg being most common.

Melatonin was generally taken at bedtime, or up to an hour before sleep, which naturally aligns with its biological role as a regulator of the circadian rhythm. This dosing flexibility, while it complicates the formulation of precise recommendations, also illustrates the relative robustness of the effect observed across different protocols.

A safety profile that reassures researchers

Perhaps the most encouraging point in this synthesis concerns the supplement's safety. Unlike opioids, melatonin carries no known risk of chemical dependency or respiratory depression, two major dangers associated with the powerful painkillers currently prescribed at large scale across North America and Europe.

The most commonly reported side effects in the trials, namely nausea, dizziness and headaches, occurred at rates nearly identical to those seen in placebo groups, and no serious adverse events were reported during the trial periods, generally limited to under three months.

Cost, a heavyweight argument in the debate over access to care

A pill for under two dollars

In a context where healthcare costs remain a major concern for Western health systems, this study's economic argument should not be underestimated. In Australia, where the research was conducted, melatonin generally costs less than 1.50 Australian dollars per tablet, a trifling price compared to certain long-term pain treatments.

This financial accessibility could, if the results are confirmed in larger-scale trials, ease the pressure on public health systems already stretched thin, particularly in chronic pain management clinics where waiting lists keep growing year after year across several Western provinces and countries.

Regulatory barriers that vary by country

Access to melatonin, however, is not uniform across the Western world. In Australia, it is generally not sold over the counter: most products require a medical prescription, though a low dose of 2 mg or less can be provided without a prescription by a pharmacist for the short-term treatment of insomnia in adults aged 55 and older.

In Canada and the United States, melatonin is sold freely as a dietary supplement, a notable regulatory difference that could either facilitate or complicate the integration of these findings into clinical practice depending on the jurisdiction concerned.

What this study does not yet tell us

A methodological heterogeneity that complicates interpretation

It would be dishonest to present this synthesis as definitive, universal proof. Other work published in the scientific literature, notably a 2020 study in the Journal of Clinical Medicine, found more mixed results when isolating high-quality trials, with associations sometimes non-significant depending on the subgroups analyzed.

This variability is a reminder of a fundamental rule in medical research: a meta-analysis, however vast, remains dependent on the quality of the individual trials that compose it, and heterogeneity across populations, dosages and pain-measurement methods can blur the real signal.

Specific trials that showed no benefit

A recent trial focused specifically on neuropathic pain, published in fall 2025, found no statistically significant difference between melatonin and placebo among 30 participants followed under a rigorous crossover protocol. This kind of contrasting result should prompt caution: melatonin clearly does not work the same way depending on the type of pain involved.

The authors of the new synthesis themselves acknowledge that larger-scale trials, with standardized protocols, will be necessary to confirm and refine our understanding of melatonin's true analgesic potential across different patient populations.

The cautious view of the researchers themselves

A complement, not a replacement

The central message conveyed by the Sydney team deserves to be repeated with emphasis: melatonin is not presented as a substitute for existing treatments, but rather as a potential complement within a multimodal approach to pain management. "Our advice is not that melatonin should replace all painkillers," Kangchao Wu clarified in communications surrounding the publication.

He insists instead on supervised use: "after consulting a doctor, it can be used as a complement to existing treatments, particularly for people who also suffer from sleep problems." This cautious wording contrasts with the sometimes alarmist or excessively optimistic tone of certain media coverage of health discoveries.

The importance of prior medical consultation

The researchers also note that melatonin can interact with other medications and is not without risk for certain populations, particularly people already taking treatments for complex underlying conditions. Consulting a healthcare professional remains, in their view, an essential step before any use intended for pain relief.

This measured approach illustrates well the difference between a legitimate scientific discovery and a promise of miracle healing, a distinction that the Western public, flooded with information on social media, sometimes struggles to make correctly.

A broader context: the global opioid crisis

A dependence on painkillers that worries the West

This discovery comes amid a opioid crisis that continues to wreak havoc across North America, with tens of thousands of overdose-related deaths every year in the United States and Canada. Any credible alternative, even a partial one, capable of reducing dependence on these high-risk medications deserves to be taken seriously by Western health authorities.

Nonsteroidal anti-inflammatory drugs, also commonly used against chronic pain, likewise carry long-term risks to the digestive, cardiovascular and renal systems, particularly among elderly patients who take them daily for years.

One path among many, not a single solution

It would nonetheless be naive to believe that melatonin, on its own, could resolve a public health crisis as complex as that of painkillers. It instead fits into a broader range of strategies including physiotherapy, cognitive-behavioral therapies and better overall management of sleep and lifestyle.

Western health systems would benefit from integrating these complementary options more systematically, rather than continuing to rely almost exclusively on conventional pharmaceutical prescriptions to treat often multifactorial chronic pain.

The biological mechanisms behind the analgesic effect

A documented anti-inflammatory and antioxidant action

On the biological level, several earlier studies have explored the mechanisms through which melatonin might exert an effect on pain. It appears to act by suppressing certain pro-inflammatory cytokines such as tumor necrosis factor alpha, while reinforcing anti-inflammatory mediators. Its antioxidant properties might also reduce the oxidative stress involved in sensitizing the nerve pathways of pain.

Melatonin also interacts with several neurotransmitter systems, notably the serotonergic, dopaminergic and GABAergic pathways, underscoring its potential role in the central modulation of pain, beyond its well-known function of regulating sleep.

Complex interactions with the opioid system

Preclinical work also suggests that melatonin might interact with the endogenous opioid system, potentially reducing tolerance to morphine while preserving its analgesic efficacy in certain animal models. This lead, while promising, remains largely at the preclinical stage and requires much further validation in humans.

These multiple mechanisms, though only partially understood, help explain why researchers describe melatonin as a pleiotropic modulator rather than a conventional analgesic in the classic sense of the term.

The next steps expected by the scientific community

Larger clinical trials needed

To turn this promising synthesis into a firm clinical recommendation, the scientific community expects larger randomized clinical trials to be conducted, with standardized protocols allowing researchers to better isolate melatonin's specific effect according to the precise type of chronic pain being treated.

Ongoing studies such as the SLEEP-FIT project, currently recruiting in Sydney and Brisbane, could eventually provide further answers about the interaction between sleep and chronic pain management in a larger population.

A cautious integration into existing clinical protocols

In the meantime, several clinicians might begin to consider melatonin as a reasonable addition to certain treatment plans, particularly for patients whose chronic pain is accompanied by documented sleep disorders, while maintaining appropriate medical supervision.

This gradual approach, rather than a rushed large-scale adoption, matches the responsible scientific process that the authors themselves appear to favor in their public communications surrounding this discovery.

The patient perspective on this new option

An overall favorable but cautious attitude

A survey of 254 people suffering from chronic musculoskeletal pain, published in the journal Physiotherapy, explored patients' perceptions of using melatonin for pain management. The results show that 73% of respondents reported sleep disorders, with insomnia being the most common form, a figure confirming the extent of overlap between these two health issues.

Notably, 40% of participants had already used melatonin, mainly for sleep, but 57% of them said they were uncertain about its actual analgesic effects. Despite this uncertainty, willingness to try melatonin for pain management remained high, at 79% among prior users and 83% among non-users.

Legitimate concerns that persist

The concerns expressed by patients in this survey mainly involved potential side effects, drug interactions, actual efficacy of the treatment and its long-term cost, all in all legitimate worries for anyone considering adding a new product to their daily treatment regimen.

This data suggests that a good deal of the work ahead for clinicians will involve not only assessing melatonin's clinical efficacy, but also better informing patients about what it can, and cannot, accomplish in their chronic pain management journey.

The economic weight of chronic pain on Western societies

A burden that goes far beyond the health system alone

Chronic musculoskeletal pain is not just an individual medical issue: it also constitutes a considerable economic burden for Western societies, between direct healthcare costs, lost workplace productivity and the prolonged disabilities that often result for those most affected.

Low-cost solutions like melatonin, if their efficacy is confirmed in larger trials, could potentially ease part of this burden, particularly within public health systems where access to advanced treatments often remains limited by waiting lists and significant budget constraints.

A potential impact on large-scale prescribing

If future research confirms the current results, a gradual integration of melatonin into standard clinical protocols could be envisioned for certain patient categories, which could eventually modestly reduce the pressure to prescribe more costly and potentially riskier medications.

This prospect, however, remains hypothetical until larger clinical trials, specifically designed to evaluate this precise use, are completed and published in peer-reviewed journals recognized by the international scientific community.

Lessons drawn from the most rigorous clinical trials

A hierarchy of evidence that separates good studies from less reliable ones

Researchers at the University of Sydney did not treat all clinical trials the same way: they applied a rigorous methodological quality grid to distinguish well-designed studies, with adequate randomization and solid control groups, from those with flaws likely to bias results upward or downward.

This distinction proved crucial: the trials judged most methodologically rigorous showed a slightly higher effect, around ten points on the pain scale, compared to the overall average of nine points calculated across all twenty-three trials included in the synthesis.

Why methodological quality changes everything in interpretation

A hurried reader might be tempted to remember only the most optimistic figure, but scientific rigor demands understanding why certain trials produce sharper results: often, it comes down to better-defined patient inclusion criteria, longer follow-up, or more standardized pain measurement.

This demand for methodological transparency is precisely what distinguishes a credible synthesis from a mere compilation of favorable results, and it is a standard Western health authorities should systematically require before authorizing new therapeutic indications for over-the-counter supplements.

International comparisons and cultural differences toward pain

Very diverse populations included in the global synthesis

The strength of this synthesis also lies in the geographic diversity of the populations studied: patients in the United States, Russia, Brazil, Egypt and China took part in the various clinical trials included, which strengthens the external validity of the conclusions on a global scale.

This diversity is not a trivial detail: it suggests that the observed analgesic effect is not specific to a particular genetic population or to a specific cultural context of pain management, but appears instead to be relatively universal among adults suffering from chronic musculoskeletal pain.

Western health systems that could benefit differently from these results

In Western countries where access to specialized care remains uneven depending on region and income, a therapeutic option as affordable as melatonin could represent a tool for health equity, particularly for rural or low-income populations already struggling to see chronic pain specialists.

This dimension of health equity deserves to be highlighted in the Western public debate, where inequalities in access to healthcare remain a major political issue, whether in Canada, the United States or Europe, despite very different health systems from one another.

The role of Western regulatory authorities in the face of this discovery

A responsibility for cautious public communication among health agencies

Faced with the publicity surrounding this synthesis, Western regulatory agencies, whether Health Canada, the U.S. FDA or their European counterparts, bear a particular responsibility: to clearly communicate the limits of this research without discouraging further, more thorough studies.

Poorly calibrated communication could either fuel excessive enthusiasm for self-medication with melatonin at inappropriate doses, or unfairly discredit a therapeutic avenue that deserves serious and methodical scientific development.

The challenge of standardizing products sold in pharmacies

A persistent problem in the field of supplements like melatonin remains the variability in actual concentration between different commercial products, with certain independent laboratories having already demonstrated significant gaps between the dose stated on the label and the dose actually present in the tablet.

This question of industrial standardization should, in my view, be an integral part of any serious discussion about the future integration of melatonin into clinical management protocols for chronic pain in the West.

Conclusion: measured hope that deserves attention, not hype

A real but still incomplete advance

This synthesis from the University of Sydney represents a serious and well-documented contribution to our understanding of melatonin's analgesic potential. With data from 2,028 participants spread across 23 trials conducted on several continents, it offers a statistically robust signal, even though methodological gray areas persist, particularly regarding the dose-response relationship and variability by type of pain.

The central message remains one of measured caution: melatonin might help some patients reduce their dependence on riskier painkillers, but it replaces neither a rigorous medical diagnosis nor a personalized treatment plan established with a healthcare professional.

What to remember before drawing hasty conclusions

In a context where the opioid crisis continues to weigh heavily on Western health systems, every credible alternative path deserves to be explored with rigor, without giving in to the media hype that too often accompanies this kind of scientific publication.

Melatonin will not cure anyone of severe chronic pain on its own, but for certain well-selected and well-supervised patients, it could represent an additional tool, inexpensive and relatively safe, within a comprehensive approach to pain management that remains, even today, one of the greatest challenges of modern medicine.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limitations

I am neither a physician nor a pharmacology researcher. I am a columnist who synthesizes and interprets published research, drawing on verifiable sources and the public statements of the study's authors. My role is not to prescribe treatment, but to help the reader understand the issues and nuances of a recent scientific discovery.

I had no access to any raw study data beyond what was published and publicly disseminated by the University of Sydney and by the scientific media cited as sources. I interviewed no one for this article and claim no personal clinical expertise in pain management.

My method and my acknowledged biases

I have a favorable bias toward rigorous science communication and I systematically favor caution in the face of announcements of medical breakthroughs, having seen too many false health promises collapse over time. This bias likely leads me to emphasize a study's limitations more than some readers might wish to see presented in a more optimistic light.

Anyone suffering from chronic pain should consult a qualified healthcare professional before making any change to their treatment, including adding an over-the-counter supplement like melatonin.

Sources

Primary sources

Melatonin may safely reduce chronic musculoskeletal pain, study finds — News-Medical, July 1, 2026

Does Melatonin Help Reduce Chronic Pain? — Neuroscience News, July 1, 2026

Efficacy and effectiveness of melatonin for the management of musculoskeletal pain — PAIN, June 30, 2026

Secondary sources

La melatonina muestra potencial como analgésico seguro y barato — Infobae, July 2, 2026

Melatonin could help reduce chronic pain — ABC, July 3, 2026

Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized Trials — Journal of Clinical Medicine

Melatonin for neuropathic pain: a double-blind, placebo-controlled trial — PubMed, November 2025